Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences
Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences
复制标题
DOI：
10.1080/14622200600789767
复制
发表时间：
2006-10-01
影响因子：
4.7
通讯作者：
Hatsukami, Dorothy
中科院分区：
文献类型：
--
作者：
King, Andrea;de Wit, Harriet;Hatsukami, Dorothy
这项双盲、安慰剂对照试验评估了纳洛酮作为标准戒烟治疗辅助药物的疗效。参与者（N=110）是表示有兴趣戒烟的成年男性和女性尼古丁依赖吸烟者。所有受试者均接受6次行为咨询（1小时/次，持续6周），以及1个月的尼古丁贴片（前2周21 mg，第3周14 mg，第4周7 mg）。受试者被随机分配到纳洛酮组或安慰剂组。纳洛酮组在戒烟日期前3天开始每天25 mg，并在戒烟日期和8周后增加至50 mg/天。在药物治疗结束时，纳洛酮组的戒烟率优于安慰剂组（纳洛酮组为48%，安慰剂组为41%），但这种差异没有统计学意义。然而，男性和女性在几个方面存在差异：在安慰剂组中，女性的戒烟率明显低于男性（39%对67%，p
This double- blinded, placebo- controlled trial evaluated the efficacy of naltrexone as an adjunct to standard smoking cessation treatment. Participants (N=110) were adult male and female nicotine-dependent smokers who expressed interest in quitting smoking. All subjects received six sessions of behavioral counseling (1 hr/session for 6 weeks), and 1 month of the nicotine patch (21 mg for the first 2 weeks, 14 mg the third week, 7mg the fourth week). Subjects were randomly assigned to the naltrexone or placebo group. The naltrexone group started at 25 mg daily for 3 days prior to the quit date, and increased to 50 mg/day on the quit date and following 8 weeks. At the end of medication treatment, the naltrexone group had better quit rates versus the placebo group (48% quit on naltrexone vs. 41% on placebo), but this difference was not statistically significant. However, men and women differed on several measures: in the placebo group, women had significantly lower quit rates than men (39% vs. 67%, p